CIDEB 体细胞功能缺失突变通过增加脂解和脂肪酸氧化减轻肝脂肪变性
研究将21种CIDEB体细胞突变引入细胞评估功能,并用小鼠模型追踪Cideb突变克隆。多数突变损害功能,功能缺失克隆在CDA-HFD喂养下被正选择;Cideb敲除小鼠对WD、CDA-HFD和酒精性肝病有保护作用,其中CDA-HFD模型效果最强。机制上Cideb缺失通过ATGL和PPARα激活增强β氧化。
要点
- 多数CIDEB体细胞突变损害功能,功能缺失克隆在CDA-HFD喂养下被正选择。
- Cideb敲除小鼠对WD、CDA-HFD和酒精性肝病有保护作用,CDA-HFD模型效果最强。
- Cideb缺失通过ATGL和PPARα激活增强肝脏脂肪酸β氧化。
核心结论
- Cideb缺失对某些类型的脂肪肝病保护作用更强,β氧化是Cideb保护机制的重要组分。
- CIDEB抑制代表一种有前景的方法,CIDEB体细胞突变可能预测最受益的患者人群。
研究设计与样本
- 将21种CIDEB体细胞突变引入细胞评估功能。
- 采用体内筛选在小鼠中追踪Cideb突变克隆,小鼠分别喂食正常饲料、西方饮食(WD)和胆碱缺乏、L-氨基酸定义的高脂饮食(CDA-HFD)。
- 构建组成性和条件性Cideb敲除小鼠研究Cideb在肝病中的作用。
- 利用同位素示踪评估脂肪酸氧化和从头脂肪生成,采用转录组学、脂质组学和代谢分析探索分子机制。
- 采用双敲除模型(Cideb/Atgl和Cideb/Pparα)检验Cideb缺失的机制。
主要发现
- 多数CIDEB突变损害功能,功能缺失克隆在CDA-HFD下被正选择,但并非所有致脂肪变性饮食均如此。
- Cideb敲除小鼠对WD、CDA-HFD和酒精诱导的肝病有保护作用,其中CDA-HFD模型效果最强。
- 肝细胞特异性Cideb缺失在MASLD(代谢功能障碍相关脂肪性肝病)建立后改善疾病,模拟治疗性小干扰RNA的影响。
- Cideb缺失通过增加β氧化保护肝脏,具体通过ATGL和PPARα激活实现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Somatic and germline CIDEB mutations are associated with protection from chronic liver diseases. The mechanistic basis and whether CIDEB suppression would be an effective therapy against fatty liver disease remain unclear. METHODS: Twenty-one CIDEB somatic mutations were introduced into cells to assess functionality. In vivo screening was used to trace Cideb mutant clones in mice fed normal chow, western diet (WD), and choline-deficient, L-amino acid-defined, high-fat diet (CDA-HFD). Constitutive and conditional Cideb knockout mice were generated to study Cideb in liver disease. Isotope tracing was used to evaluate fatty acid oxidation and de novo lipogenesis. Transcriptomics, lipidomics, and metabolic analyses were utilized to explore molecular mechanisms. Double knockout models (Cideb/Atgl and Cideb/Pparα) tested mechanisms underlying Cideb loss. RESULTS: Most CIDEB mutations impaired function, and loss-of-function clones were positively selected under CDA-HFD but not all steatogenic diets. Cideb knockout mice were protected from WD-, CDA-HFD-, and alcohol-induced liver disease, with the strongest effect in CDA-HFD models. Hepatocyte-specific Cideb deletion ameliorated disease after MASLD (metabolic dysfunction-associated steatotic liver disease) establishment, modeling the impact of therapeutic small-interfering RNAs. Cideb loss protected livers via increased β-oxidation, specifically through ATGL and PPARα activation. CONCLUSIONS: Cideb deletion is more protective in some types of fatty liver disease. β-oxidation is an important component of the Cideb protective mechanism. CIDEB inhibition represents a promising approach, and somatic mutations in CIDEB might predict the patient populations who will benefit the most. IMPACT AND IMPLICATIONS: It is not clear why somatic and germline CIDEB mutations are protective in metabolic dysfunction-associated steatotic liver disease (MASLD). Cideb mutations are predominantly loss of function, and Cideb-deficient clones selectively expand in specific dietary contexts such as choline-deficient, L-amino acid-defined, high-fat diet-induced MASLD. Consistently, liver-wide deletion of Cideb ameliorates MASLD most profoundly after choline-deficient, L-amino acid-defined, high-fat diet feeding. Mechanistically, Cideb deficiency enhances hepatic fatty acid β-oxidation via ATGL and PPARα activation. These findings suggest that CIDEB inhibition might be most effective in patients with the subtypes of MASLD that promote the expansion of CIDEB mutant clones.
引用
- Zeng Q, Patel S, Wang X, et al. Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation. J Hepatol. 2025. PMID: 40618957. doi:10.1016/j.jhep.2025.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。